Next, the panel zoomed in on the benefit of (omitting) axillary surgery. Referring to the - recently updated - results of the AMAROS trial , suggesting equal outcomes between axillary surgery and axillary radiotherapy in terms of recurrence and/or disease-free survival but with less morbidity after radiotherapy, the majority of the panellists voted for omitting complementary axillary surgery as long as radiotherapy of the axilla and positive sentinel nodes was planned. This was the case both for patients (T1-2 with 1 or 2 positive sentinel nodes) who had undergone breast-conserving surgery (73% of the panellists voted for omitting axillary surgery) and patients who had a mastectomy (83% of the panellists voted for omitting axillary surgery). However, in case of patients with 1 or 2 positive sentinel nodes undergoing mastectomy and for whom no regional node irradiation was planned, 66% of the panellists voted against omitting axillary surgery. In addition, a majority (61%) of t...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Bladder Cancer in Young Patients Next Article
Focus on treatment of erectile dysfunction and Peyronie’s disease »
Table of Contents: BCC 2019
St. Gallen Consensus
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.